Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiotoxicity of 5-flourouracil: two case reports.

A Tutkun1, S Inanli, O Caymaz

  • 1Marmara Universitesi Hastanesi, Kulak Burun Bogaz ABD, Tophanelioglu cad. no: 13-15, 81190 Altunizade, Istanbul, Turkey. selcukinanli@hotmail.com

Auris, Nasus, Larynx
|March 10, 2001
PubMed
Summary

Cardiotoxicity from 5-fluorouracil (5-FU) chemotherapy is a serious risk, often linked to coronary artery vasospasm. Careful patient selection and monitoring during 5-FU infusion are crucial to manage this rare but severe side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of small airway dysfunction by impulse oscillometry (IOS) in COPD and IPF patients.

European review for medical and pharmacological sciences·2023
Same author

Biallelic KITLG variants lead to a distinct spectrum of hypomelanosis and sensorineural hearing loss.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Variants in CIB2 cause DFNB48 and not USH1J.

Clinical genetics·2017
Same author

Variations in Multiple Syndromic Deafness Genes Mimic Non-syndromic Hearing Loss.

Scientific reports·2016
Same author

Phospholipid studies of marine organisms: V(1) new α-methoxy acids fromHigginsia tethyoides.

Lipids·2016
Same author

What is the neutrophil/lymphocyte ratio in sarcoidosis?

Bratislavske lekarske listy·2016

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • 5-fluorouracil (5-FU) is a widely used chemotherapy agent.
  • Cardiotoxicity is an increasingly recognized, albeit rare, side effect of 5-FU treatment.
  • The incidence of 5-FU cardiotoxicity is rising due to its frequent use in various chemotherapy regimens.

Observation:

  • 5-FU cardiotoxicity manifests as ischemic symptoms and signs.
  • These adverse cardiac events typically occur during the later stages of drug administration.
  • Coronary artery vasospasm and the toxic metabolite flouroacetate are proposed as primary mechanisms.

Findings:

  • The exact mechanism of 5-FU-induced cardiotoxicity is not fully elucidated, with several theories proposed.
  • Coronary artery vasospasm and flouroacetate, a toxic metabolite, are commonly implicated.

Related Experiment Videos

  • Ischemic cardiac events are observed during the late phase of 5-FU administration.

    • Implications:

    • Close monitoring of patients during 5-FU infusion is mandatory, particularly those with pre-existing coronary artery disease.
    • There is currently no single effective treatment or prophylactic measure for 5-FU cardiotoxicity.
    • Careful patient selection for 5-FU therapy and prompt discontinuation upon symptom onset are essential management strategies.